Successful TONADO 1&2 studies for tiotropium+ olodaterol combination for COPD- Boehringer

Boehringer Ingelheim presented the first data from the pivotal Phase III TONADO 1&2 studies (NCT01431274/NCT01431287) for the fixed-dose combination (FDC) of tiotropium plus olodaterol delivered via the Respimat inhaler in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD). The data were presented at the European Respiratory Society (ERS) International Congress 2014 in Munich.

Once-daily tiotropium + olodaterol FDC is an investigational combination that includes the long-acting muscarinic antagonist (LAMA) tiotropium with olodaterol, a long-acting beta agonist (LABA), delivered via the propellant-free Respimat inhaler, which generates a slow-moving mist. The pivotal 52-week TONADO� 1&2 studies included more than 5,500 patients with COPD. Results showed that lung function, as measured by trough forced expiratory volume in one second (FEV1), improved in patients receiving tiotropium + olodaterol FDC delivered via the Respimat inhaler, and that St. George's Respiratory Questionnaire (SGRQ) total score was affected favourably compared to those receiving olodaterol or tiotropium alone.